Conference abstractPublished 28 Nov 2024
Determination of novelty in organic chemistry for patentable inventions
Thermo Fisher Scientific, UK
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Patents are the primary motivation behind investment in the pharmaceutical R&D. There are four requirements to get invention patented that are novelty, inventive steps, industrial application, and should not be excluded from being patented. Novelty, particularly in organic synthesis, is one of the essential criteria to determine whether inventions are patentable or not. In the specific area of chemical synthesis in drug discovery, it is very critical to analyze novelty. There are various reasons: 1, one Markush structure (Fig. 1) has many atoms such as C, H, O, N, F, I, C etc. and elimination, addition or exchange of any atom can make a completely new molecule. Therefore, one general formula of a class of compounds can be transformed into millions of compounds with different permutations and combinations. 2, change in a single atom can result in a considerable shift in the physical and chemical properties of the molecule. Hence, it is not easy to enjoy a patent monopoly in drug development because the highly variable potential of chemical structure has made it easier for a competitor to invalidate or overcome protected inventions in drug synthesis on the grounds of novelty and inventive steps. This can be seen in Dr. Reddy (UK) Limited vs Eli Lilly's case where the claimant drug company Dr. Reddy UK (DR-UK), sought revocation of a European patent owned by the defendant, Eli Lilly (Lilly). The patent was about an anti-psychotic drug, olanzapine, used to treat schizophrenia under the brand 'Zyprexa.' Lilly had filed a provisional application in Great Britain in 1974 and disclosed a broad class of compounds. The exact olanzapine (Fig. 2a) was not mentioned in the provisional application. Also, Lilly's research leader published three research papers for several compounds with the general formula (Fig. 2a) with neuroleptic properties in 1980, 1982, and 1989 without mentioning olanzapine. After a few years of provisional application, Lilly patented olanzapine compounds in 1990. DR-UK opposed Lilly's patent being invalidated because it lacked novelty and would be obvious to a person skilled in the art based on their previous provisional application and published papers that disclosed a general formula. A decision was made by Judge Mr. Floyd at England and Wales High Court on October 13, 2008, in favour of Lilly. As such, no prior art was available about olanzapine during the patent application by Lilly. The decision was significant in the evolution of patent law related to chemical structure. In addition, many other court cases in pharmaceutical drug discovery were resolved based on Lilly's case outcome.
Subjects
ChemistryPharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMedicinal Chemistry
- SubjectChemistry
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Sunil Kumar”
